
We claim:

1. A combination of, a) a compound of Formula Ia:



Ia,

or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder.

2. The combination of claim 1 wherein the hyperproliferative disorder is cancer.

3. The combination of claim 2 wherein the cancer is associated with PTEN mutation.

4. The combination of claim 2 wherein the cancer is associated with AKT mutation, overexpression or amplification.

5. The combination of claim 2 wherein the cancer is associated with PI3K mutation.

6. The combination of claim 2 wherein the cancer is associated with Her2/ErbB2 amplification.


7. The combination of any one of claims 2-6 wherein cancer is selected from, breast, lung, ovarian, prostate, melanoma, gastric, colon, renal, head and neck, and giloma.

8. The combination of any one of claims 1-7 wherein the combination provides a synergistic effect in treating the hyperproliferative disorder.

9. The combination of claim 8 wherein Combination Index value of the synergistic effect is less than about 0.8.

10. A compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, for therapeutic use for improving the quality of life of a patient treated for a hyperproliferative disorder with erlotinib or a pharmaceutically acceptable salt thereof.

11. Use of a combination of, a) a compound of Formula Ia:



Ia,

or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal.

12. The combination of a) a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1; and b) erlotinib or a pharmaceutically acceptable salt thereof for treating a disease or condition modulated by AKT kinase.


13. The use of a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1 in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal, wherein erlotinib or a pharmaceutically acceptable salt thereof is to be administered to the mammal.

14. A kit comprising a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, a container, and a package insert or label indicating the administration of the compound of formula Ia with erlotinib or a pharmaceutically acceptable salt thereof for treating a hyperproliferative disorder.

15. A product comprising a compound having formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, and erlotinib or a pharmaceutically acceptable salt thereof as a combined preparation for separate, simultaneous or sequential use in the treatment of a hyperproliferative disorder.

We claim:


1. A combination of, a) a compound of Formula Ia:



Ia,

or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the therapeutic treatment of a hyperproliferative disorder.

2. Use of a combination of, a) a compound of Formula Ia:



Ia,

or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a hyperproliferative disorder in a mammal.

3. The use of claim 2, wherein compound of formula Ia or the salt thereof is to be administered simultaneously with erlotinib.

4. The use of claim 2, wherein the compound of formula Ia or the salt thereof is to be administered sequentially with erlotinib.

5. The use of claim 2, wherein the compound of formula Ia or the salt thereof and erlotinib are to be administered separately.

6. The use of any one of claims 2-5, wherein the hyperproliferative disorder is cancer.

7. The use of any one of claims 2-5, wherein the cancer is associated with PTEN mutation.

8. The use of any one of claims 2-5, wherein the cancer is associated with AKT mutation, overexpression or amplification.

9. The use of any one of claims 2-5, wherein the cancer is associated with PI3K mutation.

10. The use of any one of claims 2-5, wherein the cancer is associated with Her2/ErbB2 amplification.

11. The use of any one of claims 2-10 wherein cancer is selected from, breast, lung, ovarian, prostate, melanoma, gastric, colon, renal, head and neck, and glioma.

12. The use of any one of claims 2-11, wherein the combination provides a synergistic effect in treating the hyperproliferative disorder.

13. The use of claim 12 wherein Combination Index value of the synergistic effect is less than about 0.8.

14. The combination of a) a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1; and b) erlotinib or a pharmaceutically acceptable salt thereof for treating a disease or condition modulated by AKT kinase.

15. The use of a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1 in the preparation of a medicament for the treatment of a hyperproliferative disorder in a mammal, wherein erlotinib or a pharmaceutically acceptable

salt thereof is to be administered to the mammal.

16. A kit comprising a compound of formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, a container, and a package insert or label indicating the administration of the compound of formula Ia with erlotinib or a pharmaceutically acceptable salt thereof for treating a hyperproliferative disorder.

17. A product comprising a compound having formula Ia or a pharmaceutically acceptable salt thereof as defined in claim 1, and erlotinib or a pharmaceutically acceptable salt thereof as a combined preparation for separate, simultaneous or sequential use in the treatment of a hyperproliferative disorder.